Menarini Group's Obicetrapib Application Accepted by EMA for Cholesterol Treatment Menarini Group announces that EMA has accepted its applications for Obicetrapib and Obicetrapib/Ezetimibe to treat adults with primary hypercholesterolemia. This could revolutionize cholesterol management.

Menarini Group's Obicetrapib Application Accepted by EMA for Cholesterol Treatment #Italy #Florence #Menarini_Group #Obicetrapib #Cholesterol_Treatment